{"id":"096c8f797322","type":"article","url":"https://hartvaat.nl/2026/10/24/obicetrapib-heeft-geen-nadelig-effect-op-de-glycemische-waarden-en-verlaagt-moge/","title":"Obicetrapib heeft geen nadelig effect op de glycemische waarden en verlaagt mogelijk het risico op nieuwe diabetes — BROADWAY/BROOKLYN","title_en":"Effect of Obicetrapib on Glycaemia and New-Onset Diabetes: Pooled Analysis of BROADWAY/BROOKLYN and an Updated Meta-analysis of CETP Inhibitor Trials.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"European journal of preventive cardiology","doi":"10.1093/eurjpc/zwag551","source_url":"https://doi.org/10.1093/eurjpc/zwag551","authors":["Julia Brandts","Michael Szarek","Stephen J Nicholls","Fotios Barkas","Michael H Davidson","John J P Kastelein","Kausik K Ray"],"significance":6,"published":"2026-11-02","source_date":"2026-10-24","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"","summary_en":"A pooled analysis of phase 3 trials (BROADWAY/BROOKLYN) and an updated meta-analysis evaluated the impact of the CETP inhibitor obicetrapib on glycaemia and new-onset diabetes in 1,700 participants without baseline diabetes. Obicetrapib did not increase HbA1c compared with placebo and was associated with a numerically lower risk of new-onset diabetes (OR 0.69; 95% CI 0.47–1.03), consistent with a class-wide signal of reduced diabetes risk across six CETP inhibitor trials (RR 0.84; 95% CI 0.79–0.90). These findings address a key safety concern with intensive lipid-lowering therapy, though definitive cardiovascular outcomes await the ongoing PREVAIL trial.","created":"2026-10-26T02:44:18Z","updated":"2026-10-26T02:44:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"In een gepoolde analyse van fase 3-onderzoeken (BROADWAY/BROOKLYN) en een bijgewerkte meta-analyse werd het effect van de nieuwe CETP-remmer obicetrapib op de glycemische waarden en het ontstaan van diabetes onderzocht bij 1.700 deelnemers zonder diabetes. Obicetrapib verhoogde HbA1c niet ten opzichte van placebo en werd geassocieerd met een lager risico op nieuwe diabetes (OR 0,69; 95% BI 0,47-1,03), een signaal dat in de meta-analyse van zes trials werd bevestigd (RR 0,84; 95% BI 0,79-0,90). Deze bevindingen zijn geruststellend voor de klinische toepassing, aangezien nieuwe diabetes een bekende bezorgdheid is bij intensieve LDL-C-lowering; definitieve cardiovasculaire uitkomsten van obicetrapib staan nog uit.","abstract_original":"AIMS: New-onset diabetes (NoD) is a recognised effect of statin therapy potentially influencing acceptance of intensive LDL-C-lowering. In contrast, cholesteryl ester transfer protein (CETP) inhibition has been associated with lower NoD risk in earlier trials. We assessed the effect of the highly selective CETP inhibitor obicetrapib on glycaemia and NoD, contextualised within an updated meta-analysis of CETP inhibitor trials. METHODS: Individual participant data from the phase 3 BROADWAY and BROOKLYN trials were pooled across 1,700 participants without diabetes at baseline (899 normoglycaemic, 801 prediabetes; 38.8% women), randomised 2:1 to obicetrapib 10 mg or placebo for 52 weeks. The PRISMA-compliant, PROSPERO-registered systematic review identified six eligible trials reporting NoD. Pooled risk ratios were calculated using Mantel-Haenszel fixed-effect models, with prespecified subgroup analyses by baseline glycaemic status and CETPi potency, and trial-level meta-regression. RESULTS: Obicetrapib did not increase HbA1c at week 52 vs placebo (LSMD -0.02%, 95% CI -0.04 to 0.00). NoD occurred in 6.4% (obicetrapib) versus 8.5% (placebo) (adjusted OR 0.69, 95% CI 0.47-1.03), directionally consistent across glycaemic strata. Restricted cubic spline analyses identified associations between HDL-C, apoA1 and Lp(a) changes and NoD risk, but not HbA1c change. In the meta-analysis, CETP inhibition was associated with a 16% lower risk of NoD (RR 0.84, 95% CI 0.79-0.90; I2 = 0%). CONCLUSIONS: Obicetrapib did not adversely affect glycaemia and was associated with a numerically lower risk of NoD, consistent with a CETP inhibitor class signal of a modestly lower risk. The PREVAIL trial will provide larger-longer evidence about obicetrapib and NoD."}